- 3DS Will Demonstrate its Innovative Virtual Surgical Planning (VSP ® ) Technology, Used Worldwide by Surgeons to Plan Reconstructive Surgeries
- In-Booth Live Demonstrations Will Showcase Personalized Surgical Planning Solutions that are Changing How Surgeons Prepare for Individual Surgeries
ROCK HILL, S.C., Sept.
Independence Realty Trust, Inc. (“IRT”) (NYSE MKT: IRT) today announced
the completion of the following two acquisitions of apartment
communities for purchase prices aggregating $52.2 million:
IRT funded the cash portion of these purchase prices with a portion of
the net proceeds of IRT’s offering of its shares of common stock
completed in July 2014.
Riverbed Technology (NASDAQ:RVBD), the leader in application performance
infrastructure, today announced that Linkon, an independent supplier of
online booking solutions for the Swedish travel industry, is using
AppResponse and SteelCentral
AppInternals to provide the visibility and tools needed to
proactively manage the performance of their online travel reservation
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse
and Alcoholism (NIAAA) announced today that they have entered into an
agreement to conduct a clinical trial of HORIZANT ®
(gabapentin enacarbil) Extended-Release Tablets as a potential treatment
for alcohol use disorder (AUD). Under the terms of the agreement,
XenoPort will supply clinical trial material and the NIAAA will conduct
and pay all other expenses associated with the proposed clinical trial
NRG Energy has entered into an agreement to purchase FCE's previously announced 1.4 megawatt fuel cell power plant project at University of Bridgeport NRG Energy will acquire long-term power purchase agreement for clean and efficient distributed power generation with predictable cash flows
DANBURY, Conn., Sept.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced it
has expanded its global license agreement with CURx Pharmaceuticals,
Inc. to also include the development and commercialization of Ligand’s
Captisol-enabled™ Lamotrigine program.
Senesco Technologies, Inc. (OTCQB:SNTI) (the “Company” or “Sevion”), a
clinical-stage company which discovers, develops and acquires
next-generation biologics for the treatment of cancer and immunological
diseases, announced today a corporate rebranding under which the Company
will change its name to Sevion
Therapeutics, Inc. The
Company will continue to trade as SNTI until a new ticker symbol is
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.